|
A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Incyte; Merck |
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Incyte; Incyte; Merck |
|
|
Consulting or Advisory Role - Sanofi/Aventis |
|
|
Consulting or Advisory Role - Castle Biosciences; Roche |
Research Funding - Castle Biosciences (Inst); Regeneron (Inst); Takara Bio (Inst) |
Travel, Accommodations, Expenses - Roche |
|
|
Stock and Other Ownership Interests - GE Healthcare |
Consulting or Advisory Role - Bristol-Myers Squibb; Celyad; EMD Serono; Lion Biotechnologies; Omniseq |
Research Funding - Alkermes (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merrimack (Inst) |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Roche/Genentech |
Travel, Accommodations, Expenses - Amgen; Merck |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Immunocore; Merck; Novartis; Roche |
Research Funding - Immunocore (Inst); Merck (Inst); Prometheus (Inst) |
|
|
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; Incyte; Merck; Newlink Genetics; Novartis; OncoSec |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); GreenPeptide (Inst); Incyte (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Prometheus (Inst); Prometheus (Inst) |